AshwagandhavsSulbutiamine

Ashwagandha's withanolide compounds (withaferin A, withanolide A, withanone) modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) signaling, thereby lowering cortisol production by 25-30% in stressed individuals. It acts as a GABA-A receptor positive allosteric modulator at the benzodiazepine site, producing anxiolytic effects without sedation. Ashwagandha inhibits acetylcholinesterase (AChE), raising acetylcholine levels in the hippocampus and cortex. The withanolides have anti-inflammatory properties via inhibition of NF-κB and COX-2, and antioxidant effects that reduce neuroinflammation and oxidative stress. It may support neurogenesis through upregulation of BDNF and its receptor TrkB, and modulation of the PI3K/Akt pathway.

Sulbutiamine consists of two thiamine (vitamin B1) molecules connected by a disulfide bridge, conferring lipophilicity and efficient blood-brain barrier penetration via passive diffusion. In the brain, it is hydrolyzed to thiamine and increases thiamine diphosphate (TDP) levels—the cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase, enzymes critical for glucose metabolism and the Krebs cycle. Sulbutiamine upregulates D1 dopamine receptors in the prefrontal cortex, possibly through reduced receptor internalization or increased expression. It modulates glutamatergic transmission (affecting NMDA/AMPA receptor function) and enhances cholinergic transmission. The anti-fatigue and memory-enhancing effects likely stem from improved neuronal glucose oxidation, increased ATP production, and enhanced dopaminergic and cholinergic tone in cognitive circuits.